Practice Management

Top Story

Gottlieb sees ‘watershed opportunity’ to shape future of FDA’s regulatory process

Gottlieb sees ‘watershed opportunity’ to shape future of FDA’s regulatory process
November 16, 2017

WASHINGTON — When diagnosed with Hodgkin lymphoma at the age of 33 years, FDA Commissioner Scott Gottlieb, MD, was told he had a 90% chance of survival.

“Ninety percent doesn’t sound so good if it’s you,” Gottlieb, now 44, told HemOnc Today following a keynote presentation at the Friends of Cancer Research Annual Meeting. “So, to me, that 10% sounded pretty grim.”

In the Journals Plus

Endocrine-disrupting chemicals necessitate emphasis on iodine nutrition in breast-feeding mothers

November 16, 2017
Although breast-feeding women in the U.S. overall met WHO-recommended iodine levels for lactating women, environmental perchlorate and thiocyanate exposure may…
In the Journals Plus

DCCT: Intensive control may blunt only short-term CV effects of weight gain in type 1 diabetes

November 16, 2017
Adults with type 1 diabetes who gained excessive weight during a 6-year, intensive glycemic management regimen experienced a cardiovascular event rate over 13 years…
Meeting News

AMA adopts new strategy for genetic tests, therapeutics

November 15, 2017
AMA recently voted to advance the development of a comprehensive strategy that allows more consistent coverage of genomic and genetic tests and precision medicine, a…
More Headlines »
CME

Practical Lipidology® Volume 4, Number 1: Focus on LDL Reduction and PCSK9 Inhibition

This activity is supported by an educational grant from Amgen

A preponderance of data shows that low-density lipoprotein cholesterol (LDL-C) plays a causal role in atherosclerotic…
More »
Video
Meeting News

VIDEO: Anabolic agents should be prescribed early for high-risk osteoporosis

October 17, 2017
More »
Resource Centers
ObesityWeek

ObesityWeek

CNE CME CPE

What You Need to Know About Familial Chylomicronemia Syndrome: Pathophysiology, Diagnosis, Management, and the Patient Perspective

This activity is supported by an educational grant from Akcea Therapeutics™ A Subsidiary of Ionis Pharmaceuticals, Inc.
Endorsed by: The National Lipid Association.

Familial chylomicronemia syndrome (FCS) is a rare genetic disease that leads to severe hypertriglyceridemia and…
More »
Advertisement
Advertisement